| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/13/2005 | US20050008664 Leukemia therapy; anticancer agents |
| 01/13/2005 | US20050008660 Compositions and methods for use of alginate dural sealants |
| 01/13/2005 | US20050008656 Compositions and methods for an orally administered inhibitor of biting insects |
| 01/13/2005 | US20050008640 Method of treating transplant rejection |
| 01/13/2005 | US20050008633 Chemical and physical modulators of bioavailability of inhaled compositions |
| 01/13/2005 | US20050008630 Preservation; nutrients; foods; using ascorbic and citric acid; oxidation resistance; by-product inhibition |
| 01/13/2005 | US20050008613 Immobilized on solid carrier; reducing concentration of microbiocides; water purification; foods |
| 01/13/2005 | US20050008611 Agent for the prevention and treatment of sexually transmitted diseases-I |
| 01/13/2005 | US20050008610 Vascular site in mammals |
| 01/13/2005 | US20050008609 Multi-component reverse thermo-sensitive polymeric systems |
| 01/13/2005 | US20050008607 Composition containing a carbonyl amine |
| 01/13/2005 | US20050008596 Composition containing an oxidation-sensitive active principle and a polyisobutylene polymer |
| 01/13/2005 | US20050008590 Effective method for regulating the appearance of skin |
| 01/13/2005 | US20050008587 Cosmetic and dermatological photoprotective formulations with a content of hydroxybenzophenones, triazine derivatives and/or benzotriazole derivatives |
| 01/13/2005 | US20050008581 Methods and compositions that enhance bioavailability of coenzyme-Q10 |
| 01/13/2005 | US20050008578 HFC solution formulations containing an anticholinergic |
| 01/13/2005 | US20050008568 Complex containing dithiocarbamate compound |
| 01/13/2005 | US20050006159 Mounting configuration and method for a motorcycle seat |
| 01/13/2005 | DE4423078B4 Verfahren zur Herstellung einer Carbamazepin-Arzneiform mit verzögerter Wirkstofffreisetzung A process for the preparation of a carbamazepine pharmaceutical form with delayed release of active ingredient |
| 01/13/2005 | DE202004009564U1 Composition providing sustained release of tamsulosin, useful for treating difficulty in urination caused by prostatic hypertrophy, has controlled ratio of plasma concentration, 24 hours after administration, to maximum concentration |
| 01/13/2005 | DE10328180A1 Verwendung von Isomalt als Präbiotikum Use of isomalt as a prebiotic |
| 01/13/2005 | DE10327138A1 Use of patchouli oil, patchouli alcohol or their derivatives to inhibit asexual reproduction of fungi, reduce adhesion of microorganisms to surfaces or prepare compositions for treating microbial infections |
| 01/13/2005 | DE10327134A1 Use of patchouli oil, patchouli alcohol or their derivatives to inhibit asexual reproduction of fungi, reduce adhesion of microorganisms to surfaces or prepare compositions for treating microbial infections |
| 01/13/2005 | CA2778309A1 Methods of inhibiting vascular permeability and apoptosis |
| 01/13/2005 | CA2778126A1 Methods of inhibiting vascular permeability and apoptosis |
| 01/13/2005 | CA2756586A1 Modulation of survivin expression |
| 01/13/2005 | CA2734066A1 Modified fluorinated nucleoside analogues |
| 01/13/2005 | CA2734055A1 Modified fluorinated nucleoside analogues |
| 01/13/2005 | CA2734052A1 Modified fluorinated nucleoside analogues |
| 01/13/2005 | CA2733842A1 Modified fluorinated nucleoside analogues |
| 01/13/2005 | CA2572324A1 Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor |
| 01/13/2005 | CA2533312A1 Transdermal hormone delivery system: compositions and methods |
| 01/13/2005 | CA2532066A1 Use of [3.2.0] heterocyclic compounds and analogs thereof for the treatment of cancer, inflammation and infectious diseases |
| 01/13/2005 | CA2531412A1 Synthesis of .beta.-l-2'-deoxy nucleosides |
| 01/13/2005 | CA2531327A1 Compounds and therapeutical use thereof |
| 01/13/2005 | CA2531284A1 Metabolite of quetiapine |
| 01/13/2005 | CA2531142A1 Use of aurora kinase inhibitors for reducing the resistance of cancer cells |
| 01/13/2005 | CA2531138A1 (-)-hydroxycitric acid for controlling inflammation |
| 01/13/2005 | CA2531136A1 Parathyroid hormone (pth) containing pharmaceutical compositions for oral use |
| 01/13/2005 | CA2531083A1 Prolyl oligopeptidase inhibitors ameliorating recovery from brain trauma |
| 01/13/2005 | CA2531081A1 Composition for treating and/or preventing dysfunctions associated with type 2 diabetes mellitus and insulin resistance |
| 01/13/2005 | CA2531062A1 Compositions and methods for use of a protease inhibitor and adenosine for preventing organ ischemia and reperfusion injury |
| 01/13/2005 | CA2531061A1 Pyrimidines useful as modulators of voltage-gated ion channels |
| 01/13/2005 | CA2531060A1 Heterocyclically-substitued pentanol derivatives, process for their production and their use as anti-inflammatory agents |
| 01/13/2005 | CA2531050A1 Pharmaceutical compounds |
| 01/13/2005 | CA2530922A1 Aivlosin for the treatment of disease due to brachyspira pilosicoli or ornithobacterium rhinotracheale |
| 01/13/2005 | CA2530886A1 Dual nk1/nk3 antagonists for treating schizophrenia |
| 01/13/2005 | CA2530884A1 Trp-p8 active compounds and therapeutic treatment methods |
| 01/13/2005 | CA2530880A1 The combination of a serotonin reuptake inhibitors and agomelatine |
| 01/13/2005 | CA2530863A1 Use of alpha-ketoglutaric acid for the treatment of malnutrition or high plasma glucose condition |
| 01/13/2005 | CA2530816A1 Amide-substituted 1,2,4-triazin-5(2h)-ones for the treatment of chronic inflammatory diseases |
| 01/13/2005 | CA2530808A1 Cox-2 and faah inhibitors |
| 01/13/2005 | CA2530594A1 Methods for treating and preventing cardiac arrhythmia |
| 01/13/2005 | CA2530494A1 Formulations for the treatment of arthritis conditions |
| 01/13/2005 | CA2530483A1 Compositions containing a serotonin selective reuptake inhibitor and a 5-ht2a receptor antagonist |
| 01/13/2005 | CA2530446A1 Process for the preparation of amorphous form of a platelet aggregation inhibitor drug |
| 01/13/2005 | CA2530317A1 Pyrrolodihydroisoquinolines useful in the treatment of cancer |
| 01/13/2005 | CA2530316A1 Pyrrolodihydroisoquinolines as pde10 inhibitors |
| 01/13/2005 | CA2530215A1 Salinosporamides and methods for use thereof |
| 01/13/2005 | CA2530157A1 Barrier formulation comprising a silicone based emulsion |
| 01/13/2005 | CA2530119A1 Buffered compositions for dialysis |
| 01/13/2005 | CA2530116A1 Use of roscovitine for treating lymphocytic leukemia |
| 01/13/2005 | CA2530114A1 Pyrrolo-dihydroisoquinoline derivatives as pde10 inhibitors |
| 01/13/2005 | CA2530081A1 Ophthalmic compositions for treating ocular hypertension |
| 01/13/2005 | CA2529571A1 Macrocyclic compounds having aspartic protease inhibiting activity and pharmaceutical uses thereof |
| 01/13/2005 | CA2529558A1 Agent inducing increase in bone mass |
| 01/13/2005 | CA2529510A1 Sirt1 modulators for manipulating cells/organism lifespan/stress response |
| 01/13/2005 | CA2529322A1 Sulfonamide substituted imidazoquinolines |
| 01/13/2005 | CA2529318A1 Methods of inhibiting vascular permeability and apoptosis |
| 01/13/2005 | CA2529204A1 Use of alverine, alone or in combination with a tricyclic antidepressant or an antidepressant which is a specific inhibitor of serotonin reuptake for treatment of depression |
| 01/13/2005 | CA2528963A1 Rna interference mediated treatment of alzheimer's disease using short interfering nucleic acid (sina) |
| 01/13/2005 | CA2528913A1 Method for treating alcoholic hepatitis |
| 01/13/2005 | CA2528686A1 Dna-based aptamers for human cathepsin g |
| 01/13/2005 | CA2528119A1 Cis-2,4,5-triaryl-imidazolines |
| 01/13/2005 | CA2528084A1 Sppls as modifiers of the p53 pathway and methods of use |
| 01/13/2005 | CA2527908A1 Mylks as modifiers of branching morphogenesis and methods of use |
| 01/13/2005 | CA2527905A1 Nadks as modifiers of branching morphogenesis and methods of use |
| 01/13/2005 | CA2525968A1 Metabolites of tricyclic amides useful for inhibition of g-protein function and methods of treatment of proliferative diseases |
| 01/13/2005 | CA2525801A1 1- (alkylaminoalkyl-pyrolidin-/piperidinyl) -2, 2-diphenylacetamide derivatives as muscarinic receptor antagonists |
| 01/13/2005 | CA2524495A1 Modulation of survivin expression |
| 01/13/2005 | CA2518716A1 Inhibition of viral pathogenesis |
| 01/12/2005 | EP1496076A1 Hydrophilic polymer derivate with y type branch and preparation method of it medical composite comprising above compound |
| 01/12/2005 | EP1496064A1 Nitrate active principle |
| 01/12/2005 | EP1496058A1 Novel N-(heterobicycloalkanes)-substituted Indoles or heteroderivatives thereof |
| 01/12/2005 | EP1496056A1 Novel compounds and antimalarials |
| 01/12/2005 | EP1496054A1 Medicinal composition for improving angiotension-regulating function of blood vessel endothelium |
| 01/12/2005 | EP1496053A1 Kappa-opioid receptor agonist comprising 2-phenylbenzothiazoline derivative |
| 01/12/2005 | EP1496052A1 Novel aminobenzamide derivative |
| 01/12/2005 | EP1496051A1 Method for preparing 6-aminomethyl-6,11-dihydro-5h-dibenz(b,e)azepine |
| 01/12/2005 | EP1496037A1 Hyaluronic acid modification product |
| 01/12/2005 | EP1495768A1 Preventives/remedies for hotflash |
| 01/12/2005 | EP1495763A1 Therapeutic cream for dermatitis |
| 01/12/2005 | EP1495762A1 Therapeutic lotion for dermatitis |
| 01/12/2005 | EP1495761A1 Remedies |
| 01/12/2005 | EP1495759A1 Solid dispersion composition |
| 01/12/2005 | EP1495758A2 Formulations and methods for treatment of mucosal associated conditions with an immune response modifier |
| 01/12/2005 | EP1495757A1 Phosphodiesterase iv inhibitor containing pyridylacrylamide derivative |
| 01/12/2005 | EP1495756A1 Severe sepsis preventive therapeutic agent |
| 01/12/2005 | EP1495755A1 Use of citrulline for the manufacture of a medicament in the treatment of intestinal failure |
| 01/12/2005 | EP1495754A2 Method and composition for treating cancers |